Information  X 
Enter a valid email address

Verseon Corporation (VERS)

  Print      Mail a friend

Friday 18 October, 2019

Verseon Corporation

Announcement of 2019 Annual General Meeting

RNS Number : 4387Q
Verseon Corporation
18 October 2019

Press release

October 18, 2019


Verseon Corporation

("Verseon" or the "Company")


Announcement of 2019 Annual General Meeting

FREMONT, Calif.-Verseon Corporation (AIM:VERS), the clinical-stage pharmaceutical company developing products and technologies to advance global health, today announces that its 2019 Annual General Meeting ("AGM") will be held on October 28, 2019, at 9 a.m. local time at the Critosphere Cowork Space, 7100 Stevenson Blvd. Fremont, CA 94538, USA.

At the AGM, the Company will seek shareholder approval for the following matters:

(a)  Re-election of non-executive Class I Directors Dr. Thomas Hecht and Dr. Sangtae Kim

(b)  The sale of the Company's headquarters

The Company seeks shareholder approval or ratification for the sale of its research, development, and operations facility located at 47071 Bayside Parkway, Fremont, California (the "Property") to provide working capital for the Company. Further details of the sale will be announced via RNS without delay once available in accordance with AIM Rules ahead of the AGM. If this is not possible, a separate notice of general meeting will be sent to shareholders to approve the sale of the Property and this building sale resolution will be withdrawn from the AGM.

(c)   Such other business as may properly come before shareholders present, in person or by proxy

Copies of the 2019 AGM Proxy Information Statement are available to view and download between October 18 and October 28, 2019 from the Company's website at

- Ends -


For further information, please contact

Verseon Corporation

Sebastian Wykeham / Tina Schlafly

+1 (510) 225 9000



Arden Partners (NOMAD and Joint Broker)


Ruari McGirr / Ciaran Walsh / Dan Gee-Summons (Corporate Finance) / Fraser Marshall (Equity Sales)

+44 (0) 20 7614 5900



Cantor Fitzgerald Europe (Joint Broker) 


Phil Davies

+44 (0) 20 7894 7000


For trade and pharma media enquiries, please contact

Vane Percy & Roberts


Simon Vane Percy

+44 (0) 1737 821 890


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t